Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | STAT3 | P40763 | 3/20 | 0.53 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.53 |
| ▸ | PTPRC | P08575 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | RECQL | P46063 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anthrarufin SCHEMBL29874705 | 0.82 | MAOA (1.00) | MAOAMAPTALDH1A1MAPK1TDP1 | |
| Anthrarufin SCHEMBL29363946 | 0.82 | MAOA (1.00) | MAOAMAPTALDH1A1MAPK1TDP1 | |
| Anthrarufin SCHEMBL187843 | 0.82 | MAOA (1.00) | MAOAMAPTALDH1A1MAPK1TDP1 | |
| Anthrarufin SCHEMBL28196883 | 0.80 | MAOA (0.95) | MAOAMAPTALDH1A1MAPK1TDP1 | |
| Anthrarufin SCHEMBL27169537 | 0.80 | MAOA (0.95) | MAOAMAPTALDH1A1MAPK1TDP1 | |
| Anthrarufin SCHEMBL28419741 | 0.80 | MAOA (0.95) | MAOAMAPTALDH1A1MAPK1TDP1 | |
| SCHEMBL4402747 | 0.78 | MAOA (0.91) | MAOAMAPTALDH1A1MAPK1TDP1 | |
| SCHEMBL206335 | 0.78 | CES1 (0.79) | PABPC1DNMT1PTPRCCES1 | |
| Anthrarufin SCHEMBL25355428 | 0.77 | MAOA (0.86) | MAOAMAPTALDH1A1MAPK1TDP1 | |
| 1-Hydroxyanthraquinone SCHEMBL145303 | 0.77 | MAOA (0.86) | MAOAMAPTALDH1A1MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2436669-B1 | Preparation of anticancer-active tricyclic compounds via alkyne coupling reaction | TAHEEBO JAPAN CO LTD (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-8703979-B2 | Preparation of anticancer-active tricyclic compounds via alkyne coupling reaction | TAHEEBO JAPAN CO., LTD. (JP) | 2014-04-22 | — | — | US | disclosed |
| US-8703979-B2 | Preparation of anticancer-active tricyclic compounds via alkyne coupling reaction | TAHEEBO JAPAN CO., LTD. (JP) | 2014-04-22 | — | — | US | disclosed |
| US-20120077986-A1 | NOVEL PREPARATION OF ANTICANCER-ACTIVE TRICYCLIC COMPOUNDS VIA ALKYNE COUPLING REACTION | TAHEEBO JAPAN CO., LTD. (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20120077986-A1 | NOVEL PREPARATION OF ANTICANCER-ACTIVE TRICYCLIC COMPOUNDS VIA ALKYNE COUPLING REACTION | TAHEEBO JAPAN CO., LTD. (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20060142271-A1 | Novel lapacho compounds and methods of use thereof | MUNSTER, UNIVERSITY OF (DE) | 2006-06-29 | — | — | US | disclosed |
| EP-1551392-A2 | NOVEL LAPACHO COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004026253-A2 | NOVEL LAPACHO COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142271-A1 | Novel lapacho compounds and methods of use thereof | XIAP, PIN1, NQO1 | MAOA 2789/4885MAPT 3494/4885ALDH1A1 1710/4885 |
| US-20120077986-A1 | NOVEL PREPARATION OF ANTICANCER-ACTIVE TRICYCLIC COMPOUNDS VIA ALKYNE COUPLING REACTION | NR2C2, NR0B2, NR4A2 | MAOA 1290/4885MAPT 4425/4885ALDH1A1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.